Syndax Pharmaceuticals, Inc. Operating Income
Syndax Pharmaceuticals, Inc. (SNDX) reported Operating Income of -$39.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$39.99M.
- Syndax Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$34.20M.
- Syndax Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$62.55M.
- Syndax Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$57.43M.
- Syndax Pharmaceuticals, Inc. operating income (loss) for fiscal 2025 was -$273.08M.
- Syndax Pharmaceuticals, Inc. operating income (loss) for fiscal 2024 was -$339.67M.
- Syndax Pharmaceuticals, Inc. operating income (loss) for fiscal 2023 was -$229.95M.
- Syndax Pharmaceuticals, Inc. operating income (loss) for fiscal 2022 was -$151.76M, a 678.78% decline from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$39.99M 10-Q · filed 2026-08-04 | -$74.20M 10-Q · filed 2026-08-04 | -$136.75M derived: sum of 3 quarters · filed 2026-08-04 | -$194.17M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$34.20M 10-Q · filed 2026-04-30 | -$96.75M derived: sum of 2 quarters · filed 2026-04-30 | -$154.18M derived: sum of 3 quarters · filed 2026-04-30 | -$223.53M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$62.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$119.97M derived: sum of 2 quarters · filed 2026-02-26 | -$189.33M derived: sum of 3 quarters · filed 2026-08-04 | -$273.08M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$57.43M 10-Q · filed 2025-11-03 | -$126.78M derived: sum of 2 quarters · filed 2026-08-04 | -$210.54M 10-Q · filed 2025-11-03 | -$306.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$69.35M 10-Q · filed 2026-08-04 | -$153.11M 10-Q · filed 2026-08-04 | -$249.47M derived: sum of 3 quarters · filed 2026-08-04 | -$339.05M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$83.76M 10-Q · filed 2026-04-30 | -$180.12M derived: sum of 2 quarters · filed 2026-04-30 | -$269.70M derived: sum of 3 quarters · filed 2026-04-30 | -$343.92M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$96.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$185.94M derived: sum of 2 quarters · filed 2026-02-26 | -$260.16M derived: sum of 3 quarters · filed 2026-02-26 | -$339.67M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$89.58M 10-Q · filed 2025-11-03 | -$163.79M derived: sum of 2 quarters · filed 2025-11-03 | -$243.31M 10-Q · filed 2025-11-03 | -$321.21M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$74.22M 10-Q · filed 2025-08-04 | -$153.73M 10-Q · filed 2025-08-04 | -$231.63M derived: sum of 3 quarters · filed 2026-02-26 | -$287.99M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$79.51M 10-Q · filed 2025-05-05 | -$157.42M derived: sum of 2 quarters · filed 2026-02-26 | -$213.77M derived: sum of 3 quarters · filed 2026-02-26 | -$263.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$77.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$134.26M derived: sum of 2 quarters · filed 2026-02-26 | -$183.94M derived: sum of 3 quarters · filed 2026-02-26 | -$229.95M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$56.35M 10-Q · filed 2024-11-05 | -$106.03M derived: sum of 2 quarters · filed 2024-11-05 | -$152.05M 10-Q · filed 2024-11-05 | -$194.08M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$49.68M 10-Q · filed 2024-08-01 | -$95.69M 10-Q · filed 2024-08-01 | -$137.73M derived: sum of 3 quarters · filed 2025-03-03 | -$172.87M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$46.02M 10-Q · filed 2024-05-08 | -$88.05M derived: sum of 2 quarters · filed 2025-03-03 | -$123.19M derived: sum of 3 quarters · filed 2025-03-03 | -$160.91M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$42.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$77.17M derived: sum of 2 quarters · filed 2025-03-03 | -$114.90M derived: sum of 3 quarters · filed 2025-03-03 | -$151.76M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$35.14M 10-Q · filed 2023-11-02 | -$72.86M derived: sum of 2 quarters · filed 2023-11-02 | -$109.72M 10-Q · filed 2023-11-02 | -$13.97M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$37.72M 10-Q · filed 2023-08-03 | -$74.58M 10-Q · filed 2023-08-03 | $21.17M derived: sum of 3 quarters · filed 2024-02-27 | $1.14M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$36.86M 10-Q · filed 2023-05-08 | $58.89M derived: sum of 2 quarters · filed 2024-02-27 | $38.86M derived: sum of 3 quarters · filed 2024-02-27 | $16.52M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $95.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $75.72M derived: sum of 2 quarters · filed 2024-02-27 | $53.38M derived: sum of 3 quarters · filed 2024-02-27 | $26.22M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$20.03M 10-Q · filed 2022-11-03 | -$42.37M derived: sum of 2 quarters · filed 2022-11-03 | -$69.53M 10-Q · filed 2022-11-03 | -$89.39M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$22.33M 10-Q · filed 2022-08-08 | -$49.50M 10-Q · filed 2022-08-08 | -$69.36M derived: sum of 3 quarters · filed 2022-08-08 | -$89.21M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$27.16M 10-Q · filed 2022-05-09 | -$47.02M derived: sum of 2 quarters · filed 2022-05-09 | -$66.88M derived: sum of 3 quarters · filed 2022-05-09 | -$83.49M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$19.86M 10-K · filed 2021-03-12 | -$39.71M derived: sum of 2 quarters · filed 2021-11-15 | -$56.32M derived: sum of 3 quarters · filed 2021-11-15 | -$71.42M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$19.85M 10-Q · filed 2021-11-15 | -$36.46M derived: sum of 2 quarters · filed 2021-11-15 | -$51.56M 10-Q · filed 2021-11-15 | -$65.77M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$16.61M 10-Q · filed 2021-08-09 | -$31.71M 10-Q · filed 2021-08-09 | -$45.91M derived: sum of 3 quarters · filed 2021-08-09 | -$59.06M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | -$15.10M 10-Q · filed 2021-05-11 | -$29.30M derived: sum of 2 quarters · filed 2021-05-11 | -$42.45M derived: sum of 3 quarters · filed 2021-05-11 | -$57.83M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | -$14.21M 10-K · filed 2021-03-12 | -$27.35M derived: sum of 2 quarters · filed 2021-03-12 | -$42.73M derived: sum of 3 quarters · filed 2021-03-12 | -$57.54M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$13.15M 10-K · filed 2021-03-12 | -$28.52M derived: sum of 2 quarters · filed 2021-03-12 | -$43.33M 10-Q · filed 2020-11-05 | -$62.67M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | -$15.37M 10-K · filed 2021-03-12 | -$30.18M 10-Q · filed 2020-08-06 | -$49.52M derived: sum of 3 quarters · filed 2021-03-12 | -$67.36M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | -$14.81M 10-K · filed 2021-03-12 | -$34.14M derived: sum of 2 quarters · filed 2021-03-12 | -$51.98M derived: sum of 3 quarters · filed 2021-03-12 | -$70.94M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | -$19.33M 10-K · filed 2020-03-05 | -$37.17M derived: sum of 2 quarters · filed 2020-03-05 | -$56.13M derived: sum of 3 quarters · filed 2020-03-05 | -$75.88M 10-K · filed 2021-03-12 |
| 2018-09-30 | -$17.84M 10-K · filed 2020-03-05 | -$36.79M derived: sum of 2 quarters · filed 2020-03-05 | -$56.54M 10-Q · filed 2019-11-07 | -$76.03M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | -$18.95M 10-K · filed 2020-03-05 | -$38.70M 10-Q · filed 2019-08-07 | -$58.19M derived: sum of 3 quarters · filed 2020-03-05 | -$73.64M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | -$19.75M 10-K · filed 2020-03-05 | -$39.24M derived: sum of 2 quarters · filed 2020-03-05 | -$54.69M derived: sum of 3 quarters · filed 2020-03-05 | -$68.53M derived: sum of 4 quarters · filed 2020-03-05 |
| 2017-12-31 | -$19.49M 10-K · filed 2019-03-07 | -$34.94M derived: sum of 2 quarters · filed 2019-03-07 | -$48.78M derived: sum of 3 quarters · filed 2019-03-07 | -$61.95M 10-K · filed 2020-03-05 |
| 2017-09-30 | -$15.45M 10-K · filed 2019-03-07 | -$29.29M derived: sum of 2 quarters · filed 2019-03-07 | -$42.47M 10-Q · filed 2018-11-05 | -$53.61M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | -$13.84M 10-K · filed 2019-03-07 | -$27.02M 10-Q · filed 2018-08-08 | -$38.16M derived: sum of 3 quarters · filed 2019-03-07 | -$53.40M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | -$13.18M 10-K · filed 2019-03-07 | -$24.32M derived: sum of 2 quarters · filed 2019-03-07 | -$39.56M derived: sum of 3 quarters · filed 2019-03-07 | -$48.19M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | -$11.14M 10-K · filed 2018-03-08 | -$26.38M derived: sum of 2 quarters · filed 2018-03-08 | -$35.01M derived: sum of 3 quarters · filed 2018-03-08 | -$43.77M 10-K · filed 2019-03-07 |
| 2016-09-30 | -$15.24M 10-K · filed 2018-03-08 | -$23.87M derived: sum of 2 quarters · filed 2018-03-08 | -$32.63M 10-Q · filed 2017-11-08 | -$37.30M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | -$8.63M 10-K · filed 2018-03-08 | -$17.39M 10-Q · filed 2017-08-10 | -$22.07M derived: sum of 3 quarters · filed 2018-03-08 | -$27.92M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | -$8.75M 10-K · filed 2018-03-08 | -$13.43M derived: sum of 2 quarters · filed 2018-03-08 | -$19.29M derived: sum of 3 quarters · filed 2018-03-08 | -$24.83M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | -$4.68M 10-K · filed 2017-03-14 | -$10.54M derived: sum of 2 quarters · filed 2017-03-14 | -$16.08M derived: sum of 3 quarters · filed 2017-03-14 | -$20.51M 10-K · filed 2018-03-08 |
| 2015-09-30 | -$5.86M 10-K · filed 2017-03-14 | -$11.40M derived: sum of 2 quarters · filed 2017-03-14 | -$15.83M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | -$5.54M 10-K · filed 2017-03-14 | -$9.98M 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | -$4.43M 10-K · filed 2017-03-14 | |||
| 2014-12-31 | -$21.33M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |